ライフサイエンスコーパス: mesothelin

1 mor cells are focally positive for CA125 and mesothelin.

2 , epithelial cellular adhesion molecule, and mesothelin.

3 so produces regressions of tumors expressing mesothelin.

4 h an eukaryotic expression vector coding for mesothelin.

5 C and is very cytotoxic to cells expressing mesothelin.

6 phosphatase (PAP), Wilms tumor-1 protein, or Mesothelin.

7 ize highly immunogenic Region I (296-390) on mesothelin.

8 the immunotoxin SS1P that binds Region I of mesothelin.

9 -cell immunity to cancer antigens, including mesothelin.

10 oadhesin HN125 to interfere MUC16 binding to mesothelin.

11 oses of SS1P, a RIT whose Ab portion targets mesothelin.

12 rine mesothelioma line that stably expresses mesothelin.

13 to express the tumor-differentiation antigen mesothelin.

14 ined in the first 64-residue fragment of the mesothelin.

15 imeric receptor with high affinity for human mesothelin.

16 ted proteinase and inhibitor of metastasis), mesothelin (a cancer marker), marapsin (a trypsin-like s

17 trikingly, ligands derived from mucin 16 and mesothelin, a molecular axis of prognostic importance in

18 After three rounds of panning on recombinant mesothelin, a single-chain Fv (scFv)-displaying phage wa

19 Payload 17 was conjugated to anti-mesothelin and anti-fucosylated monosialotetrahexosylgan

20 lignant mesothelioma frequently express both mesothelin and CA125 (also known as MUC16) at high level

21 The interaction between mesothelin and CA125 may facilitate the implantation and

22 of ovarian cancer cells by interacting with mesothelin and galectin.

23 otoxicity of immunotoxin SS1P, which targets mesothelin and is currently in clinical trials for the t

24 id sequence as the membrane-bound portion of mesothelin and megakaryocyte potentiating factor (MPF).

25 ected that bound specifically to recombinant mesothelin and mesothelin-positive cells.

26 a single-chain variable fragment that binds mesothelin and that is fused to signaling domains derive

27 an carcinomas were PAX8 (paired box gene 8), mesothelin, and ephrin-B1 (EFNB1).

28 arget gene and mesothelial progenitor marker mesothelin, and many mesothelin-positive cells coexpress

29 alin2, 14-3-3sigma, trefoil factor2, S100A4, mesothelin, and prostate stem cell antigen) that were ov

30 cells interact with tumor cells through the mesothelin/anti-mesothelin axis.

31 vtansine, an antibody-drug conjugate of anti-mesothelin antibody linked to maytansinoid DM4, in patie

32 el (gavo-cel) consists of single-domain anti-mesothelin antibody that integrates into the endogenous

33 as vaccine and T-cell therapies directed at mesothelin are undergoing clinical evaluation.

34 The findings are confirmed for mesothelin as alternative tumor antigen.

35 mino acids at the N-terminal of cell surface mesothelin as the minimum fragment for complete binding

36 ving mesothelioma, a positive blood test for mesothelin at a high-specificity threshold is a strong i

37 with tumor cells through the mesothelin/anti-mesothelin axis.

38 f mesothelin shedding and could help improve mesothelin-based targeted therapies.

39 The protein has been named mesothelin because it is made by mesothelial cells.

40 These antibodies do not compete for mesothelin binding with the immunotoxin SS1P that binds

41 he signaling capacity of the entire TCR upon mesothelin binding.

42 r of mesenchymal markers including vimentin, mesothelin, bone morphogenetic protein 7, and Tweak rece

43 Mechanistically, secretion of high levels of mesothelin by metastatic cancer cells induced the expres

44 zes this CA125-binding domain and blocks the mesothelin-CA125 interaction on cancer cells.

45 tibody targeting the mesothelial cell marker mesothelin can effectively inhibit mesothelial cell to a

46 ogous human T cells electroporated with anti-mesothelin CAR mRNA.

47 ated CAF targeting induces expression of the mesothelin CAR, establishing an IF/THEN-gated circuit se

48 single amino acid substitution in CD28-based mesothelin CAR-T cells results in improved persistence a

49 ves the effectiveness of tumor-directed anti-mesothelin CAR-T cells, while simultaneous co-administra

50 n addition, a mesothelin tumor vaccine and a mesothelin- chimeric antigen receptor are being evaluate

51 However, the poor sensitivity of mesothelin clearly limits its added value to early diagn

52 new assay can also be used to measure serum mesothelin concentration in mesothelioma patients, indic

53 attenuated Listeria monocytogenes-expressing mesothelin (CRS-207, JNJ-64041757), and chimeric antigen

54 009, a humanized monoclonal antibody against mesothelin currently under clinical trials.

55 imeric antimesothelin antibody (amatuximab), mesothelin-directed antibody drug conjugates (anetumab r

56 glyco-bridge binder recognizing Tn-MUC1 into mesothelin-directed CAR-T cells.

57 ucted via monitoring the cytotoxicity of the mesothelin-directed immunotoxin SS1P.

58 n anti-mesothelin immunotoxin, was the first mesothelin-directed therapy to enter the clinic, and its

59 At 95% specificity, mesothelin displayed a sensitivity of 32% (95% CI, 26% t

60 s to multiple HLA-A2, A3, and A24-restricted mesothelin epitopes exclusively in the three patients wi

61 ll lung cancer (NSCLC) line, one targeted to mesothelin expressed by a mesothelioma cell line, and on

62 RG7787 kills many types of mesothelin-expressing cancer cells lines and causes tumo

63 18 Fv that retains full binding affinity for mesothelin-expressing cancer cells.

64 -cel warrants further study in patients with mesothelin-expressing cancers given its encouraging anti

65 therapeutic strategy to improve targeting of mesothelin-expressing cancers.

66 nitoring and treating mesothelioma and other mesothelin-expressing cancers.

67 eded to define active treatments in relapsed mesothelin-expressing malignant pleural mesothelioma.

68 activity in heavily pretreated patients with mesothelin-expressing solid tumors.

69 vo-cel in patients with treatment-refractory mesothelin-expressing solid tumors.

70 SS1scFvSA localized in the mesothelin-expressing tumor, resulting in a high accumul

71 , we studied SS1P, a 63-kDa RIT that targets mesothelin-expressing tumors and has a short serum half-

72 SS1P targets and kills mesothelin-expressing tumors, which include mesothlioma

73 al analyses revealed the association between mesothelin expression and poor overall survival, whereas

74 High levels of tumor mesothelin expression were detected in patients with cli

75 Uptake in the tumor colocalized with mesothelin expression, while uptake in the spleen coloca

76 optimized RIT consisting of a humanized anti-mesothelin Fab fused to domain III of Pseudomonas exotox

77 ent techniques to identify a binding site on mesothelin for CA125.

78 The mesothelin fragment has a compact, right-handed superhel

79 Our results demonstrate that mesothelin function is not essential for growth or repro

80 al genes in the immunotoxin pathway, such as mesothelin, furin, KDEL receptor 2, or members of the di

81 We prioritized mucin-1, mesothelin, gamma-glutamyltransferase 5, and cathepsin-E

82 We have analyzed the expression of the mouse mesothelin gene in different developmental stages and in

83 In adult tissues the mesothelin gene was expressed in lung, heart, spleen, li

84 vivo, we generated mutant mice in which the mesothelin gene was inactivated by replacing it with the

85 It kills cells expressing human mesothelin (hMSLN), which is highly expressed on the sur

86 e ongoing studies will define the utility of mesothelin immunotherapy for treating cancer.

87 SS1P, an anti-mesothelin immunotoxin, was the first mesothelin-directe

88 218 and YP223) is suitable to detect soluble mesothelin in a sandwich ELISA with high sensitivity.

89 der the possibility of dynamic expression of mesothelin in benign lung with a special concern for pat

90 The use of mesothelin in early diagnosis was evaluated by different

91 ine the diagnostic accuracy and use of serum mesothelin in early diagnosis, we performed an individua

92 These results reveal a role for mesothelin in regulating macrophage functions and intera

93 ol/L, the sensitivities and specificities of mesothelin in the different studies ranged widely from 1

94 To directly assess the function of the mesothelin in vivo, we generated mutant mice in which th

95 ultiple secondary structural elements of the mesothelin, including residues from helix alpha1, the lo

96 attenuated Listeria monocytogenes-expressing mesothelin, induces innate and adaptive immunity.

97 Mesothelin is a cell-surface glycoprotein whose expressi

98 Mesothelin is a cell-surface molecule over-expressed on

99 Mesothelin is a cell-surface tumor-associated antigen ex

100 Mesothelin is a differentiation antigen present on the s

101 Mesothelin is a glycoprotein that is overexpressed in se

102 Mesothelin is a glycosylphosphatidylinositol-linked glyc

103 Mesothelin is a tumor antigen that is highly expressed i

104 Mesothelin is a tumor differentiation antigen that is hi

105 Mesothelin is actively shed from the cell surface and is

106 Mesothelin is an antigen demonstrated previously by gene

107 Mesothelin is an emerging cell surface target in mesothe

108 Mesothelin is currently considered the best available se

109 Because among normal tissues, mesothelin is present only on mesothelial cells, it repr

110 onally, a second CAR targeting a TAA such as mesothelin is specifically integrated at a TCR signaling

111 When stimulated by mesothelin, lentivirally transduced T cells were induced

112 Mesothelin levels were standardized for between-study di

113 ary pneumocyte and not pleural expression of mesothelin may lead to dose-limiting toxicity.

114 Mesothelin may play a role in cellular adhesion.

115 ch identified 16 diagnostic studies of serum mesothelin, measured with the Mesomark enzyme-linked imm

116 sothelin overexpression (defined as 2+ or 3+ mesothelin membrane staining intensity on at least 30% o

117 The conversion of the anti-mesothelin monoclonal antibody K1 to a single-chain Fv (

118 ins comprising either the N-terminal part of mesothelin/MPF (D1Ig), reported to be easily cleaved off

119 Soluble molecules of the mesothelin/MPF family may provide useful new marker(s) f

120 A new member of the mesothelin/MPF family was discovered, which has an 82-bp

121 In homozygous mutant mice neither mesothelin mRNA nor the protein product was detected.

122 Mesothelin (MSLN) and cancer antigen125/mucin 16 (CA125/

123 on of isolated mesothelial cells highlighted mesothelin (Msln) and its binding partner mucin 16 (Muc1

124 Cell surface mesothelin (MSLN) can be solubilized and released into t

125 In this study, the efficacy of mesothelin (MSLN) CAR-T cells released from the TSPs was

126 Mesothelin (MSLN) contributes to the malignant and invas

127 R) targeting the membrane-proximal domain of mesothelin (MSLN) further improved the antitumor respons

128 Mesothelin (MSLN) may be the most "dramatic" of the tumo

129 knockout (KO) of the cancer surface antigen mesothelin (MSLN) or by introducing Y318A mutation in MS

130 We apply this paradigm to study mesothelin (MSLN) overexpression, a nearly ubiquitous, d

131 en receptor T cell (CAR T) therapy targeting mesothelin (MSLN) shows promise, but challenges such as

132 One popular target is mesothelin (MSLN) which is highly expressed on the surfa

133 ich TCRs, specific to the self/tumor antigen mesothelin (Msln), are integrated into the Trac locus, w

134 trophoblast cell surface antigen 2 (TROP-2), mesothelin (MSLN), sodium-dependent phosphate transport

135 ost prominent proteins with hydrosalpinx was mesothelin (MSLN), which until now has only been associa

136 luated the efficacy of two second-generation mesothelin (MSLN)-directed CAR T cells in orthotopic mou

137 erformed genome scale CRISPR-Cas9 screens in mesothelin (MSLN)-expressing pancreatic cancer cells.

138 Multiple clinical studies have treated mesothelin (MSLN)-positive solid tumors by administering

139 The mesothelin (MSLN)-targeted (227)Th conjugate is a novel

140 We generated a fully mouse cross-reactive mesothelin (MSLN)-targeted BiTE molecule that is genetic

141 By engineering LiPSC-GR1.1 with a mesothelin (MSLN)-targeting CAR and interleukin-15 (IL-1

142 : This article reports the evaluation of the mesothelin (MSLN)-TTC conjugate (BAY 2287411) in combina

143 ibulin 2, and the recently identified marker mesothelin (MSLN).

144 ially expressed genes identified by PCA were Mesothelin, Muc4, Muc5A/C, Kallikrein 10, Transglutamina

145 crystal structure of the complex between the mesothelin N-terminal fragment and Fab of MORAb-009 at 2

146 Binding of mesothelin on normal mesothelial cells lining the pleura

147 The limited expression of mesothelin on normal tissues and its high expression in

148 h as melanoma cell adhesion molecule (MCAM), mesothelin, or human epidermal growth factor receptor 2

149 31, 2017, 589 patients were enrolled and 248 mesothelin-overexpressing patients were randomly allocat

150 Participants were prospectively screened for mesothelin overexpression (defined as 2+ or 3+ mesotheli

151 and RG7787 act synergistically to kill many mesothelin-positive cancer cell lines and produce major

152 elial progenitor marker mesothelin, and many mesothelin-positive cells coexpressed albumin.

153 d specifically to recombinant mesothelin and mesothelin-positive cells.

154 via a bystander mechanism and protected the mesothelin-positive targets from apoptosis rather than l

155 ently reported that an immunotoxin targeting mesothelin produced durable major tumor regressions in p

156 RG7787 (anti-mesothelin recombinant immunotoxin) is highly cytotoxic

157 To study dysfunction of mesothelin-redirected CAR T cells in pancreatic cancer,

158 Mesothelin secretion by cancer cells supports pancreatic

159 Here, we identified that mesothelin secretion by pancreatic cancer cells co-opts

160 We have found that mesothelin sheddase activity is mediated by a TNF-alpha

161 dings provide a mechanistic understanding of mesothelin shedding and could help improve mesothelin-ba

162 act through TACE as endogenous regulators of mesothelin shedding.

163 th CARs specific for the human tumor antigen mesothelin showed greatly enhanced cytokine production a

164 vidual tumor cells along with levels of shed mesothelin (sMSLN), a barrier of SS1P therapy.

165 survival and toxicity, and the induction of mesothelin specific T cell responses.

166 immunotoxin composed of the Fv portion of a mesothelin-specific antibody fused to a bacterial toxin

167 ges, we developed allogeneic IL-15-enhanced, mesothelin-specific CAR-engineered invariant natural kil

168 two partial resection xenograft models using mesothelin-specific CARTs.

169 Enhanced mesothelin-specific CD8 T-cell responses were associated

170 ddition, the post-immunotherapy induction of mesothelin-specific CD8+ T cells in HLA-A1+ and HLA-A2+p

171 Functionally, coexpressing IFPs with a mesothelin-specific T cell receptor improved tumor killi

172 ntigen-related cell adhesion molecule 6, and mesothelin, suggest potential use as diagnostic markers.

173 Incorporation of a spacer-into the mesothelin surface antigen or the cancer drug itself-con

174 o subsequent treatment with a tumor antigen (mesothelin)-targeted CAR T cells and to anti-PD-1 antibo

175 ed (PD-1-mediated) T cell exhaustion affects mesothelin-targeted CAR T cells and explored cell-intrin

176 herapies, such as peptide-based vaccines and mesothelin-targeted chimeric antigen receptor T cells, h

177 RG7787 is a mesothelin-targeted immunotoxin designed to have low-imm

178 to enter the clinic, and its use showed that mesothelin-targeted therapy was safe in patients.

179 While in the process of characterizing mesothelin-targeted TR3 variants using a single chain an

180 man T cells engineered with a clinical-stage mesothelin-targeting CAR to determine whether its disrup

181 red to display human DR18 potently activated mesothelin-targeting chimeric antigen receptor (CAR) NK

182 essing a chimeric antigen receptor targeting mesothelin, the T cells exhibited enhanced intratumoral

183 s required and sufficient for the binding of mesothelin to CA125.

184 The 2.5-kb mesothelin transcript was detected in the mRNA of E 7.0,

185 The A431-K5 mesothelin transfected cell line was used as the target.

186 In addition, a mesothelin tumor vaccine and a mesothelin- chimeric anti

187 mor responses have prompted us to review how mesothelin was discovered and the advances that led to t

188 or developments over the past 20 years since mesothelin was first identified in our laboratory.

189 rmalities were detected in any tissues where mesothelin was reportedly expressed in wild-type mice.

190 revealed that claudin 4, CXCR4, S100A4, and mesothelin were expressed at significantly high frequenc

191 a chimeric antigen receptor that recognizes mesothelin were more effective at clearing human mesothe

192 expression of cell surface antigens such as mesothelin, which is overexpressed in mesothelioma, ovar

193 dvanced or metastatic disease overexpressing mesothelin who had progressed on first-line platinum-pem

194 The purified immunotoxin binds mesothelin with high affinity (Kd 11 nm), is stable for